ArticleJournal of experimental & clinical cancer research : CR2022

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist.

Yu Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.